Analyst Price Targets — TNXP
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| August 10, 2026 5:53 pm | — | Raymond James | $27.00 | $12.54 | TheFly | Tonix Pharmaceuticals price target raised to $27 from $25 at Raymond James |
| June 24, 2026 8:30 pm | — | Raymond James | $26.00 | $12.10 | TheFly | Tonix Pharmaceuticals initiated with a Strong Buy at Raymond James |
Latest News for TNXP
Tonix Pharmaceuticals NASDAQ: TNXP is focusing its near-term strategy on the commercial launch of TONMYA for fibromyalgia while advancing development programs in Lyme disease prevention and major depressive disorder, Chief Executive Officer Seth Lederman said during a Canaccord Genuity conference presentation.
Tonix Pharmaceuticals (NASDAQ: TNXP) reported second-quarter 2026 net product revenue of approximately $13.5 million, led by $11 million in sales of fibromyalgia treatment Tonmya. The company said Tonmya sales rose 197% from the first quarter, its second full quarter of commercial sales following the product's November launch. Revenue also included approximately $2.5 million from migraine products
Tonix Pharmaceuticals Holding Corp. (TNXP) Q2 2026 Earnings Call Transcript
Tonix Pharmaceuticals NASDAQ: TNXP reported second-quarter 2026 net product revenue of approximately $13.5 million, led by $11 million in sales of fibromyalgia treatment Tonmya. The company said Tonmya sales rose 197% from the first quarter, its second full quarter of commercial sales following the product's November launch.
TONMYA® net sales totaled approximately $11 million, an increase of 197% quarter-over-quarter Commercial and government payer coverage for TONMYA meaningfully expanded, now reaching approximately 136 million covered lives (43% of total U.S. lives) First patient enrolled in Phase 2 HORIZON study of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) 5.6 mg for the treatment of major depressive disorder (MDD) Phase…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TNXP.
U.S. House Trading
No House trades found for TNXP.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.